249 related articles for article (PubMed ID: 25369798)
1. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
BMC Med; 2014 Nov; 12():203. PubMed ID: 25369798
[TBL] [Abstract][Full Text] [Related]
2. Risk of grade 3-4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: A meta-analysis of 18 randomized controlled clinical trials.
Miroddi M; Sterrantino C; Simonelli I; Ciminata G; Phillips RS; Calapai G
Crit Rev Oncol Hematol; 2015 Nov; 96(2):355-71. PubMed ID: 26160607
[TBL] [Abstract][Full Text] [Related]
3. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials.
Li X; Shan BE; Wang J; Xing LP; Guo XJ; Zhang YH; Shi PH; Wang ZY
PLoS One; 2013; 8(11):e81897. PubMed ID: 24312376
[TBL] [Abstract][Full Text] [Related]
4. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.
Wang Q; Qi Y; Zhang D; Gong C; Yao A; Xiao Y; Yang J; Zhou F; Zhou Y
Tumour Biol; 2015 May; 36(5):3471-82. PubMed ID: 25542231
[TBL] [Abstract][Full Text] [Related]
5. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
Funakoshi T; Suzuki M; Tamura K
Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
Petrelli F; Cabiddu M; Borgonovo K; Barni S
Ann Oncol; 2012 Jul; 23(7):1672-9. PubMed ID: 22241897
[TBL] [Abstract][Full Text] [Related]
7. Risk of fatigue in cancer patients receiving anti-EGFR monoclonal antibodies: results from a systematic review and meta-analysis of randomized controlled trial.
Zhu J; Zhao W; Liang D; Li G; Qiu K; Wu J; Li J
Int J Clin Oncol; 2018 Apr; 23(2):389-399. PubMed ID: 29181651
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
9. Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies.
Cui D; Cao D; Yang Y; Qiu M; Huang Y; Yi C
Mol Biol Rep; 2014 Mar; 41(3):1291-8. PubMed ID: 24390240
[TBL] [Abstract][Full Text] [Related]
10. Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab).
Miroddi M; Sterrantino C; Simmonds M; Caridi L; Calapai G; Phillips RS; Stewart LA
Int J Cancer; 2016 Nov; 139(10):2370-80. PubMed ID: 27450994
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
[TBL] [Abstract][Full Text] [Related]
12. Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials.
Qi WX; Sun YJ; Shen Z; Yao Y
J Chemother; 2014 Dec; 26(6):359-68. PubMed ID: 24621163
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy plus targeted drugs in conversion therapy for potentially resectable colorectal liver metastases: a meta-analysis.
Wang L; Sun Y; Zhao B; Zhang H; Yu Q; Yuan X
Oncotarget; 2016 Aug; 7(34):55732-55740. PubMed ID: 27248177
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
[TBL] [Abstract][Full Text] [Related]
15. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials.
Li J; Yan H
Cancer Chemother Pharmacol; 2018 Oct; 82(4):571-583. PubMed ID: 30006755
[TBL] [Abstract][Full Text] [Related]
16. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X; Lacouture ME; Jia Y; Wu S
Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
[TBL] [Abstract][Full Text] [Related]
17. Mucositis with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of randomized controlled trials.
Li J; Xie J
Jpn J Clin Oncol; 2018 Aug; 48(8):718-727. PubMed ID: 29893861
[TBL] [Abstract][Full Text] [Related]
18. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
19. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis.
Pietrantonio F; Cremolini C; Petrelli F; Di Bartolomeo M; Loupakis F; Maggi C; Antoniotti C; de Braud F; Falcone A; Iacovelli R
Crit Rev Oncol Hematol; 2015 Oct; 96(1):156-66. PubMed ID: 26088456
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
Wei F; Shin D; Cai X
Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
